[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE229972T1 - Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung - Google Patents

Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung

Info

Publication number
ATE229972T1
ATE229972T1 AT96932722T AT96932722T ATE229972T1 AT E229972 T1 ATE229972 T1 AT E229972T1 AT 96932722 T AT96932722 T AT 96932722T AT 96932722 T AT96932722 T AT 96932722T AT E229972 T1 ATE229972 T1 AT E229972T1
Authority
AT
Austria
Prior art keywords
inhibitors
metalloproteinases
tnf release
substituted peptides
sulfur substituted
Prior art date
Application number
AT96932722T
Other languages
English (en)
Inventor
Andrew Douglas Baxter
John Gary Montana
David Alan Owen
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9520354.3A external-priority patent/GB9520354D0/en
Priority claimed from GBGB9607126.1A external-priority patent/GB9607126D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE229972T1 publication Critical patent/ATE229972T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
AT96932722T 1995-10-05 1996-10-04 Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung ATE229972T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9520354.3A GB9520354D0 (en) 1995-10-05 1995-10-05 Compounds
GBGB9607126.1A GB9607126D0 (en) 1996-04-04 1996-04-04 Compounds
PCT/GB1996/002438 WO1997012902A1 (en) 1995-10-05 1996-10-04 Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation

Publications (1)

Publication Number Publication Date
ATE229972T1 true ATE229972T1 (de) 2003-01-15

Family

ID=26307887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96932722T ATE229972T1 (de) 1995-10-05 1996-10-04 Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung

Country Status (20)

Country Link
US (1) US5981490A (de)
EP (1) EP0859784B1 (de)
JP (1) JPH11512733A (de)
KR (1) KR100472752B1 (de)
CN (1) CN1145637C (de)
AT (1) ATE229972T1 (de)
AU (1) AU710072B2 (de)
BR (1) BR9610922A (de)
CA (1) CA2229434A1 (de)
CZ (1) CZ289711B6 (de)
DE (1) DE69625506T2 (de)
DK (1) DK0859784T3 (de)
ES (1) ES2186803T3 (de)
HU (1) HUP0003760A3 (de)
IL (1) IL123430A (de)
MX (1) MX9802680A (de)
NO (1) NO981520L (de)
NZ (1) NZ319222A (de)
PL (1) PL185312B1 (de)
WO (1) WO1997012902A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
CA2280134A1 (en) * 1997-03-03 1998-09-11 David Alan Owen Selective mmp inhibitors having reduced side-effects
EP1123308A1 (de) * 1998-10-23 2001-08-16 Darwin Discovery Limited Bekannte peptide als metalloproteniase inhibitoren mit eindeutiger kristallstruktur
NL1013404C2 (nl) * 1999-10-27 2001-05-01 Dsm Nv Werkwijze voor de bereiding van een dipeptide en tussenproduct in een dergelijke werkwijze.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001087870A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic acid derivatives
JP2004518688A (ja) * 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
US20040175419A1 (en) * 2001-04-26 2004-09-09 Sprockel Omar Leopold Control of compactibility through cystallization
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
AU2002356979A1 (en) * 2001-11-30 2003-06-17 Bristol-Myers Squibb Company Method of producing n-((2s)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl)-l-leucyl-l-tert-leucine n-methylamide and intermediate thereof
US20060167334A1 (en) * 2003-06-26 2006-07-27 Anstadt Mark P Method and apparatus for direct mechanical ventricular actuation with favorable conditioning and minimal heart stress
EP1663201A4 (de) * 2003-07-15 2009-10-28 Korea Res Inst Of Bioscience Verwendung von neuen 2-oxo-heterozyklischen verbindungen sowie diesen enthaltenden pharmazeutischen zubereitungen
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CN103254291B (zh) * 2013-05-30 2014-06-25 常州亚当生物技术有限公司 肿瘤坏死因子-α多肽抑制剂及其应用
CN103285373A (zh) * 2013-05-30 2013-09-11 苏州普罗达生物科技有限公司 肿瘤坏死因子-α多肽抑制剂制备及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3889726T2 (de) * 1987-03-17 1994-10-13 Res Corp Technologies Inc Synthetische inhibitoren von säugetier-collagenase.
DE4311021A1 (de) * 1993-03-31 1994-10-27 Diagnostikforschung Inst Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel
WO1995006031A1 (en) * 1993-08-23 1995-03-02 Immunex Corporation Inhibitors of tnf-alpha secretion
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
MX9702487A (es) * 1994-10-05 1998-04-30 Darwin Discovery Ltd Compuestos peptidilo y su uso terapeutico como inhibidores de las metaloproteasas.
US5981491A (en) * 1995-05-10 1999-11-09 Darwin Discovery Limited Peptidyl compounds and their therapeutic use
US5994293A (en) * 1995-05-10 1999-11-30 Darwin Discovery Ltd. Peptidyl compounds and their therapeutic use

Also Published As

Publication number Publication date
CN1145637C (zh) 2004-04-14
NZ319222A (en) 1999-09-29
HUP0003760A3 (en) 2001-05-28
CA2229434A1 (en) 1997-04-10
US5981490A (en) 1999-11-09
EP0859784A1 (de) 1998-08-26
KR100472752B1 (ko) 2006-01-27
WO1997012902A1 (en) 1997-04-10
NO981520D0 (no) 1998-04-03
KR19990063996A (ko) 1999-07-26
IL123430A (en) 2001-04-30
HUP0003760A2 (hu) 2001-04-28
BR9610922A (pt) 1999-12-21
IL123430A0 (en) 1998-09-24
EP0859784B1 (de) 2002-12-18
DK0859784T3 (da) 2003-04-22
MX9802680A (es) 1998-11-30
PL185312B1 (pl) 2003-04-30
NO981520L (no) 1998-04-03
CN1198747A (zh) 1998-11-11
DE69625506T2 (de) 2003-07-24
AU7139896A (en) 1997-04-28
JPH11512733A (ja) 1999-11-02
CZ289711B6 (cs) 2002-03-13
AU710072B2 (en) 1999-09-16
ES2186803T3 (es) 2003-05-16
PL325824A1 (en) 1998-08-03
DE69625506D1 (de) 2003-01-30
CZ101798A3 (cs) 1998-08-12

Similar Documents

Publication Publication Date Title
ATE229972T1 (de) Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
FI973360A0 (fi) Uusia dipeptidisiä amidiineja trombiininestäjiksi
NO990548L (no) Inhibitorer for cystein-protease
NO20006716D0 (no) Proteaseinhibitorer
ATE266000T1 (de) Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
MY113489A (en) Reversible protease inhibitors
EA199900162A1 (ru) Ингибиторы клеточной адгезии
DE69509401D1 (de) Peptidische verbindungen und deren therapeutische verwendung als metalloproteinase-inhibitoren
ES2229045T3 (es) Derivados de peptidos terapeuticos.
ATE241998T1 (de) Multikatalytische protease-inhibitoren
DE69830410D1 (de) Meta-benzamidinderivate als serinprotease-inhibitoren
DE69729583D1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
NO975742D0 (no) Reversible cysteinproteasehemmere
DE69419623D1 (de) Peptidinhibitoren der urokinaserezeptor-aktivität
DE69533704D1 (de) Bradykinin-antagonist peptide mit n-substituierten glycinen
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
HK1025511A1 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
ID16105A (id) Inhibitor-inhibitor serin protease
ATE226592T1 (de) Peptide, die metallproteinasen und die tnf- freisetzung hemmen, und ihre therapeutische verwendung
PT833919E (pt) Toxina botulinica do tipo f e sua utilizacao
TR200001353T2 (tr) Metaloproteinaz inhibitörleri
BR9612344A (pt) Inibidores de proteases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0859784

Country of ref document: EP

REN Ceased due to non-payment of the annual fee